Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

hoechst ag - lincosamidi - lincosamidi

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - lincosamidi - lincosamidi

Italia - italiano - Ministero della Salute

fatro s.p.a. - lincomicina cloridrato - lincomicina cloridrato - 850 milligrammo (i), lincomicina cloridrato - 850 mg - lincosamides

Italia - italiano - Ministero della Salute

fatro s.p.a. - spectinomicina, lincomicina cloridrato monoidrato - lincomicina cloridrato monoidrato - 56.7 mg/ml; spectinomicina - 151.2 mg/ml, spectinomicina - 151.2 mg/ml; lincomicina cloridrato monoidrato - 56.7 mg/ml - lincosamides, combinations with other antibacterials

Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilessia, parziale - antiepilettici, - lacosamide ucb è indicato come monoterapia e in terapia aggiuntiva nel trattamento di parziale-inizio convulsioni con o senza secondaria generalizzazione in adulti, adolescenti e bambini a partire dai 4 anni di età con epilessia.

Unione Europea - italiano - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamide - epilessia - antiepilettici, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamide - epilessia - antiepilettici, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva b.v. - lacosamide - lacosamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

g.l. pharma gmbh - lacosamide - lacosamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - lacosamide - lacosamide